Alicia Gil, CEO Omakase Consulting attended a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation)

//Alicia Gil, CEO Omakase Consulting attended a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation)

Alicia Gil, CEO Omakase Consulting attended a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation)

Alicia Gil, CEO Omakase Consulting attended yesterday a session held in the Spanish National Congress organised by FEDER (Spanish Rare Diseases Organisation) to debate on the challenges faced by orphan drugs in Spain and the potential opportunities opening for research and access to treatments for rare diseases in the light of the European Pharmaceutical Strategy. As announced by the Spanish Healthcare Minister, Carolina Darias, back in December 2021, this strategy will be a priority for Spain during its forthcoming EU Presidency in 2023.

The session included Healthcare Commission spokesperson from different political parties, national and EU patient association representatives, national and European trade associations, the Spanish Medicines Agency, regional healthcare government and industry representatives.

At Omakase we are experts in orphan drugs  particularly interested in research in rare diseases and work to ensure much needed treatments reach patients who need them.

#rarediseases #orphandrugs #europeanpharmaceuticalstrategy #Spain

2022-06-29T09:32:53+00:00June 29th, 2022|News & Events|